DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors
Background Ototoxicity is a common adverse side effect of platinum chemotherapy and
cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, our …
cranial radiation therapy; however, individual susceptibility is highly variable. Therefore, our …
[HTML][HTML] Genetic determinants of ototoxicity during and after childhood cancer treatment: protocol for the PanCareLIFE Study
E Clemens, AJM Meijer, L Broer… - JMIR research …, 2019 - researchprotocols.org
Background: Survival rates after childhood cancer now reach nearly 80% in developed
countries. However, treatments that lead to survival and cure can cause serious adverse …
countries. However, treatments that lead to survival and cure can cause serious adverse …
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study
AJM Meijer, FA Diepstraten, T Langer, L Broer… - NPJ precision …, 2021 - nature.com
In children with cancer, the heterogeneity in ototoxicity occurrence after similar treatment
suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) …
suggests a role for genetic susceptibility. Using a genome-wide association study (GWAS) …
Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia
EGE Hurkmans, MJ Klumpers, C Dello Russo… - Frontiers in …, 2023 - frontiersin.org
Hearing loss (ototoxicity) is a major adverse effect of cisplatin and carboplatin
chemotherapy. The aim of this study is to identify novel genetic variants that play a role in …
chemotherapy. The aim of this study is to identify novel genetic variants that play a role in …
[HTML][HTML] Association between genetic polymorphisms and platinum-induced ototoxicity in children
G Lui, N Bouazza, F Denoyelle, M Moine, L Brugières… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Platinum is extensively used in the treatment of several childhood cancers. However,
ototoxicity is one of the most notable adverse effects, especially in children. Several studies …
ototoxicity is one of the most notable adverse effects, especially in children. Several studies …
Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study
Ototoxicity is a common side effect of platinum treatment and manifests as irreversible, high-
frequency sensorineural hearing loss. Genetic association studies have suggested a role for …
frequency sensorineural hearing loss. Genetic association studies have suggested a role for …
[HTML][HTML] Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European …
T Langer, E Clemens, L Broer, L Maier… - European journal of …, 2020 - Elsevier
Background Irreversible sensorineural hearing loss is a common side effect of platinum
treatment with the potential to significantly impair the neurocognitive, social and educational …
treatment with the potential to significantly impair the neurocognitive, social and educational …
The pharmacogenomics of cisplatin-induced hearing loss
K Pussegoda - 2012 - open.library.ubc.ca
Cisplatin is a widely used chemotherapeutic agent for the treatment of solid tumours. A
serious complication of cisplatin treatment is permanent hearing loss. The study hypothesis …
serious complication of cisplatin treatment is permanent hearing loss. The study hypothesis …
The Role of Inherited TPMT and COMT Genetic Variation in Cisplatin‐Induced Ototoxicity in Children With Cancer
JJ Yang, JYS Lim, J Huang, J Bass… - Clinical …, 2013 - Wiley Online Library
Ototoxicity is a debilitating side effect of platinating agents with substantial interpatient
variability. We sought to evaluate the association of thiopurine S‐methyltransferase (TPMT) …
variability. We sought to evaluate the association of thiopurine S‐methyltransferase (TPMT) …
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity
S Thiesen, P Yin, AL Jorgensen, JE Zhang… - Pharmacogenetics …, 2017 - journals.lww.com
Objectives Cisplatin ototoxicity affects 42–88% of treated children. Catechol-O-
methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic …
methyltransferase (COMT), thiopurine methyltransferase (TPMT) and AYCP2 genetic …